Evaluation of the effect of a specific survivin small interference RNA (siRNA) on proliferation and the sensitivity of HL-۶۰ acute myeloid leukemia (AML) cells to the chemotherapeutic drug etoposide

سال انتشار: 1400
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 140

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

CANCERMED05_089

تاریخ نمایه سازی: 27 دی 1400

چکیده مقاله:

Introduction & Aim: Overexpression of survivin, a known inhibitor of apoptosis, is associated with tumor progression and drug resistance in numerous malignancies, including leukemias. The aim of this study was to investigate the effect of a specific survivin small interference RNA (siRNA) on proliferation and the sensitivity of HL-۶۰ acute myeloid leukemia (AML) cells to the chemotherapeutic drug etoposide. Methods: The cells were transfected with siRNAs using Lipofectamine™۲۰۰۰ transfection reagent. Relative survivin mRNA and protein levels were measured by quantitative real-time PCR and Western blotting, respectively. Trypan blue exclusion assays were performed to monitor tumor cell proliferation after siRNA transfection. The cytotoxic effects of etoposide and survivin siRNA, alone and in combination, on leukemic cells were determined using MTT assay. Apoptosis was assessed by ELISA cell death assay. Results: Survivin siRNA markedly reduced both mRNA and protein expression levels in a time-dependent manner, leading to distinct inhibition of cell proliferation and increased spontaneous apoptosis. Surprisingly, survivin siRNA synergistically increased the cell toxic effects of etoposide. Moreover, survivin down-regulation significantly enhanced its induction of apoptosis. Conclusions: Our study suggests that down-regulation of survivin by siRNA can trigger apoptosis and overcome drug resistance of leukemia cells. Therefore, survivin siRNA may be an effective adjuvant in AML chemotherapy

کلیدواژه ها:

Survivin - siRNA - etoposide - HL-۶۰ - apoptosis

نویسندگان

Jamal Amiri

Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, I.R, Iran- Students’ Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, I.R, Iran

Hadi Karami

Department of Molecular Medicine and Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Sardasht Street, Arak